Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3729)
All Articles published online
|
Jun 21, 2007 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i23/3164.htm |
| Number | Citing Articles |
| 1 |
Brian I. Carr, Srikanth Nagalla. Hepatocellular Carcinoma. 2009; : 527 doi: 10.1007/978-1-60327-376-3_20
|
| 2 |
Marcello Maida, Giuseppe Cabibbo, Giuseppe Brancatelli, Chiara Genco, Nicola Alessi, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà. Assessment of Treatment Response in Hepatocellular Carcinoma: A Review of the Literature. Future Oncology 2013; 9(6): 845 doi: 10.2217/fon.13.33
|
| 3 |
Jia Liu, Thomas Mittendorf, J.-Matthias von der Schulenburg. A Structured Review and Guide Through Studies on Health-Related Quality of Life in Kidney Cancer, Hepatocellular Carcinoma, and Leukemia. Cancer Investigation 2010; 28(3): 312 doi: 10.3109/07357900903287022
|
| 4 |
M Caraglia, G Giuberti, M Marra, R Addeo, L Montella, M Murolo, P Sperlongano, B Vincenzi, S Naviglio, S Del Prete, A Abbruzzese, P Stiuso. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death & Disease 2011; 2(4): e150 doi: 10.1038/cddis.2011.34
|
| 5 |
Claudia Pivonello, Maria Cristina De Martino, Mariarosaria Negri, Gaia Cuomo, Federica Cariati, Francesco Izzo, Annamaria Colao, Rosario Pivonello. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infectious Agents and Cancer 2014; 9(1) doi: 10.1186/1750-9378-9-27
|
| 6 |
Chiun Hsu, Ying-Chun Shen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010; 31(1): 55 doi: 10.1016/j.cct.2009.08.002
|
| 7 |
Adam C. Yopp, William R. Jarnagin. Randomized Clinical Trials in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2010; 19(1): 151 doi: 10.1016/j.soc.2009.09.012
|
| 8 |
Ujendra Kumar. Somatostatin and Somatostatin Receptors in Tumour Biology. International Journal of Molecular Sciences 2023; 25(1): 436 doi: 10.3390/ijms25010436
|
| 9 |
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Carla Mihaela Tone, Daria Alexandra Hemes, Konstantinos Periferakis, Lamprini Troumpata, Ioana Anca Badarau, Cristian Scheau, Ana Caruntu, Ilinca Savulescu-Fiedler, Constantin Caruntu, Andreea-Elena Scheau. Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias. Current Issues in Molecular Biology 2024; 46(9): 9721 doi: 10.3390/cimb46090578
|
| 10 |
Brian I. Carr, Srikanth Nagalla, Ravit Geva. Hepatocellular Carcinoma. 2016; : 489 doi: 10.1007/978-3-319-34214-6_33
|
| 11 |
Aldona Kasprzak, Agnieszka Geltz. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review. Biomedicines 2024; 12(3): 578 doi: 10.3390/biomedicines12030578
|
| 12 |
Maximilian Schöniger-Hekele, Joachim Kettenbach, Markus Peck-Radosavljevic, Christian Müller. Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study. Journal of Experimental & Clinical Cancer Research 2009; 28(1) doi: 10.1186/1756-9966-28-142
|
| 13 |
Timothy R. Morgan. Clinical Cancer Prevention. Recent Results in Cancer Research 2010; 188: 85 doi: 10.1007/978-3-642-10858-7_7
|
| 14 |
YAO LIU, LI JIANG, YI MU. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncology Letters 2013; 6(3): 821 doi: 10.3892/ol.2013.1435
|
| 15 |
Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020; 25(17): 4012 doi: 10.3390/molecules25174012
|
| 16 |
Ioulia Evangelou, Constantina Petraki, Pavlos Msaouel, Andreas Scorilas, Eleni Sdrolia, Georgia Padazi, Vassilios Koborozos, Michael Koutsilieris. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. European Journal of Clinical Investigation 2012; 42(7): 777 doi: 10.1111/j.1365-2362.2012.02648.x
|
| 17 |
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?. Livers 2022; 2(4): 315 doi: 10.3390/livers2040024
|
| 18 |
Hanna K. Sanoff, Richard Kim, Anastasia Ivanova, Angela Alistar, Autumn J. McRee, Bert H. O’Neil. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Investigational New Drugs 2015; 33(2): 505 doi: 10.1007/s10637-015-0209-7
|
| 19 |
Xi Chen, Xiao-Yu Zhang, Yang Shen, Li-Li Fan, Mu-Lan Ren, Yong-Ping Wu. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget 2016; 7(50): 83451 doi: 10.18632/oncotarget.13120
|
| 20 |
S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola, C. Ciafardini, M. Colombo, M. Peracchi. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive and Liver Disease 2009; 41(1): 31 doi: 10.1016/j.dld.2008.05.002
|
| 21 |
Li Su, WenFang Xu. Peptidomimetics and metalloprotease inhibitors as anticancer drugs. Science in China Series B: Chemistry 2009; 52(5): 535 doi: 10.1007/s11426-009-0040-0
|
| 22 |
Nuh N. Rahbari, Arianeb Mehrabi, Nathan M. Mollberg, Sascha A. Müller, Moritz Koch, Markus W. Büchler, Jürgen Weitz. Hepatocellular Carcinoma. Annals of Surgery 2011; 253(3): 453 doi: 10.1097/SLA.0b013e31820d944f
|
| 23 |
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. International Journal of Molecular Sciences 2019; 20(19): 4811 doi: 10.3390/ijms20194811
|
| 24 |
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Ioana Anca Badarau, Andreea-Elena Scheau, Mircea Tampa, Simona Roxana Georgescu, Andreea Cristiana Didilescu, Cristian Scheau, Constantin Caruntu, Maria Beatrice Morelli. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Analytical Cellular Pathology 2021; 2021: 1 doi: 10.1155/2021/1840069
|
| 25 |
Hao-Wen Sim, Jennifer Knox, Laura A. Dawson. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2017; 26(4): 647 doi: 10.1016/j.soc.2017.05.006
|
| 26 |
Kerstin Wohlleber, Patrick Heger, Pascal Probst, Christoph Engel, Markus K. Diener, André L. Mihaljevic. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Quality of Life Research 2021; 30(9): 2429 doi: 10.1007/s11136-021-02810-8
|
| 27 |
Omar Abdel-Rahman, Angela Lamarca, Juan W Valle, Richard A Hubner. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocrine-Related Cancer 2014; 21(6): R485 doi: 10.1530/ERC-14-0389
|
| 28 |
Jean-Claude Barbare, Olivier Bouché, Franck Bonnetain, Laetitia Dahan, Catherine Lombard-Bohas, Roger Faroux, Jean-Luc Raoul, Stéphane Cattan, Alain Lemoine, Jean-Frédéric Blanc, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Sophie Cazorla, Dany Gargot, Thierry Thevenot, Emmanuel Diaz, Anne Bastie, Thomas Aparicio, Laurent Bedenne. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. European Journal of Cancer 2009; 45(10): 1788 doi: 10.1016/j.ejca.2009.02.018
|
| 29 |
Maria Cristina De Martino, Leo J. Hofland, Steven W.J. Lamberts. Neuroendocrinology - Pathological Situations and Diseases. Progress in Brain Research 2010; 182: 255 doi: 10.1016/S0079-6123(10)82011-4
|
| 30 |
Malgorzata Trofimiuk‐Müldner, Alicja Hubalewska‐Dydejczyk. Somatostatin Analogues. 2015; : 135 doi: 10.1002/9781119031659.ch12
|
| 31 |
Monica Marra, Ignazio M Sordelli, Angela Lombardi, Monica Lamberti, Luciano Tarantino, Aldo Giudice, Paola Stiuso, Alberto Abbruzzese, Rossella Sperlongano, Marina Accardo, Massimo Agresti, Michele Caraglia, Pasquale Sperlongano. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. Journal of Translational Medicine 2011; 9(1) doi: 10.1186/1479-5876-9-171
|
| 32 |
Jordi Rodon, Victoria DeSantos, Robert Jean Ferry, Razelle Kurzrock. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Molecular Cancer Therapeutics 2008; 7(9): 2575 doi: 10.1158/1535-7163.MCT-08-0265
|
| 33 |
Xi-Qing Ji, Xin-Jian Ruan, Hong Chen, Gang Chen, Shi-Yong Li, Bo Yu. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials. Medical Science Monitor 2011; 17(8): RA169 doi: 10.12659/MSM.881892
|
| 34 |
Tian-Kang Guo, Xiang-Yong Hao, Bin Ma, Ke-Hu Yang, Yi-Ping Li, Hong-Ling Li, Yuan-Hui Gu, Hui Cai, Ya-Li Liu, Yuan Li, Wei-Peng Zhan. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Journal of Cancer Research and Clinical Oncology 2009; 135(12): 1685 doi: 10.1007/s00432-009-0615-3
|
| 35 |
Marialuisa Appetecchia, Roberto Baldelli. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research 2010; 29(1) doi: 10.1186/1756-9966-29-19
|
| 36 |
Chapter 4: Chemotherapy and radiotherapy. Hepatology Research 2010; 40(s1): 74 doi: 10.1111/j.1872-034X.2010.00657.x
|
| 37 |
Dimitrios N. Samonakis, George Notas, Nikolaos Christodoulakis, Elias A. Kouroumalis. Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma: A Message Not Well Taken. Digestive Diseases and Sciences 2008; 53(9): 2359 doi: 10.1007/s10620-007-0175-9
|
| 38 |
Giuseppe Cabibbo, Marco Enea, Massimo Attanasio, Jordi Bruix, Antonio Craxì, Calogero Cammà. A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†. Hepatology 2010; 51(4): 1274 doi: 10.1002/hep.23485
|
| 39 |
Pavlos Msaouel, Evanthia Galanis, Michael Koutsilieris. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opinion on Investigational Drugs 2009; 18(9): 1297 doi: 10.1517/13543780903176399
|
| 40 |
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3911-3
|
| 41 |
G. Treiber, T. Wex, P. Malfertheiner. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. Journal of Cancer Research and Clinical Oncology 2009; 135(2): 271 doi: 10.1007/s00432-008-0443-x
|
| 42 |
Wei-Dong Jia, Ge-Liang Xu, Wei Wang, Zhi-Hua Wang, Jian-Sheng Li, Jin-Liang Ma, Wei-Hua Ren, Yong-Sheng Ge, Ji-Hai Yu, Wen-Bin Liu. A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in Mice. The Tohoku Journal of Experimental Medicine 2009; 218(2): 155 doi: 10.1620/tjem.218.155
|
| 43 |
Simone Krebs, Mark Dunphy. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; : 285 doi: 10.1016/B978-0-323-34062-5.00017-0
|